Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts: A Cost-Effectiveness Analysis
Authors:
- 15 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 192 (2) , 229-237
Abstract
Rationale: Fluoroquinolone (FQN) therapy of latent tuberculosis infection among contacts of individuals with multidrug-resistant tuberculosis (MDR-TB) is controversial. Objectives: To determine the potential benefits, risks (including acquired FQN resistance), and cost-effectiveness of FQN therapy to prevent TB in contacts of individuals with MDR-TB. Methods: We used decision analysis to estimate costs and outcomes associated with no therapy compared with a 6-month course of daily FQN therapy to treat latent TB infection in contacts of individuals with MDR-TB. Outcomes modeled were the incidence of MDR-TB, MDR-TB with FQN resistance, TB-related death, quality-adjusted life years, and health system costs. Measurements and Main Results: FQN preventive therapy resulted in health system savings, lower incidence of MDR-TB, and lower mortality than no treatment. We found the incidence of MDR-TB with acquired FQN resistance would also be lower with FQN therapy of infected contacts. Conclusions: In our model, FQN preventive therapy resulted in substantial health system savings and in reduced mortality, incidence of MDR-TB, and incidence of acquired FQN-resistant disease as well as improved quality of life. FQN therapy remained cost saving with improved outcomes even if the effectiveness of therapy in preventing MDR-TB was as low as 10%.Keywords
Funding Information
- CJ Martin Fellowship (APP1054107)
This publication has 34 references indexed in Scilit:
- What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?PLOS ONE, 2013
- Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic ReviewPLOS ONE, 2013
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLOS Medicine, 2012
- Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision AnalysisPLOS ONE, 2012
- Safety Profile of the FluoroquinolonesDrug Safety, 2010
- Fluoroquinolone Resistance in Mycobacterium tuberculosis : The Effect of Duration and Timing of Fluoroquinolone ExposureAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis : Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo EfficacyAntimicrobial Agents and Chemotherapy, 2007
- Isoniazid Preventive Therapy and Risk for Resistant TuberculosisEmerging Infectious Diseases, 2006
- Fluoroquinolone Resistance in Patients with Newly Diagnosed TuberculosisClinical Infectious Diseases, 2003